Testolactone 413a person become confused. Temporary hair loss was reported with two pa-
tients who were also taking a corticosteroid.
Abuse factors.Not enough scientific information to report about tolerance,
dependence, withdrawal, or addiction.
Drug interactions.Testolactone may promote bleeding if a person is also
taking anti–blood clot medicine.
Cancer.Testolactone’s potential for causing cancer is unknown.
Pregnancy.In rat experiments at doses far higher than humans normally
receive, the drug increased the amount of fetal malformations and deaths. No
birth defects were found when pregnant rabbits received over seven times the
normal human dose. The drug is not designed for pregnant women, and im-
pact on human pregnancy is unknown. Whether the drug passes into human
milk is unknown.
Additional scientific information may be found in:
Goldenberg, I.S., et al. “Combined Androgen and Antimetabolite Therapy of Advanced
Female Breast Cancer.”Cancer36 (1975): 308–10.
Howards, S.S. “Treatment of Male Infertility.”New England Journal of Medicine 332
(1995): 312–17.
Laue, L., et al. “Treatment of Familial Male Precocious Puberty with Spironolactone
and Testolactone.”New England Journal of Medicine320 (1989): 496–502.
“Testolactone Aqueous Suspension (Teslac).”Clinical Pharmacology and Therapeutics 11
(1970): 302–6.